Bausch + Lomb Reports Strong Q2 Results and Raises Full-Year Guidance
Bausch + Lomb reported strong second-quarter results for fiscal year 2026, with revenue rising 8% to $1.394 billion on a constant-currency basis and adjusted EBITDA increasing by 28% to $246 million. The growth was driven by favorable product mix, productivity initiatives, and lower fixed-cost intensity across its vision care, surgical, and pharmaceutical segments. The company raised its full-year revenue guidance to between $5.440 billion and $5.540 billion from a prior range of about 5.8% to 7.7%, with adjusted EBITDA now expected in the range of $1.025 billion–$1.075 billion, up by approximately $15 million. CFO Sam Eldessouky highlighted that deleveraging remains the top capital-allocation priority as net leverage stood at around 4.7 times at quarter-end. Bausch + Lomb also noted strong performance in specific product lines such as MIEBO and surgical implantables, with sales increasing by 44% and 64%, respectively. The company is anticipating key regulatory milestones for its ELIOS and enVista Beyond products.
Tickers: $BLCO